• Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Heterozygous (PubMed=22194965).
  
• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22194965; PubMed=27533468).
  
• Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=22194965; PubMed=27533468).
  

PubMed=22194965; DOI=10.1371/journal.pone.0028973; PMCID=PMC3237573
Atefi M., von Euw E.M., Attar N., Ng C., Chu C., Guo D.-L., Nazarian R., Chmielowski B., Glaspy J.A., Comin-Anduix B., Mischel P.S., Lo R.S., Ribas A.
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
PLoS ONE 6:E28973-E28973(2011)

PubMed=27533468; DOI=10.1080/15384101.2016.1208862; PMCID=PMC5026796
Malka-Mahieu H., Girault I., Rubington M., Leriche M., Welsch C., Kamsu-Kom N., Zhao Q., Desaubry L., Vagner S., Robert C.
Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
Cell Cycle 15:2405-2409(2016)